



August 25, 2022
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Disposition of Treasury Stock through Third-Party Allotment for the Purpose of Making a Donation to Kyoto University (Details determined)

August 25, 2022 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that at the Board of Directors meeting held on May 12, 2022, it resolved to conduct a disposition of treasury stock through third-party allotment for the purpose of making a donation to Kyoto University, which was approved at the 47th Ordinary General Meeting of Shareholders held on June 22, 2022.

At the Board of Directors meeting held today, JCR hereby determined the details of the subscription requirements, including the date of disposition which had been undetermined.

1. Overview of the Disposition

(1) Number of shares to be disposed	1,000,000 shares of common stock
(2) Disposition price	¥1 per share
(3) Amount to be procured	¥1,000,000
(4) Disposition method	Third-party allotment
(5) Subscriber	Kyoto University
(6) Date of disposition	September 15, 2022
(7) Other	With regard to the disposition of the treasury stock, at the 47th Ordinary General Meeting of Shareholders held on June 22, 2022, the Board of Directors received approval to be entrusted with determining the requirements based on the provisions of Article 199 and Article 200 of the Companies Act.

2. Overview of the subscriber

(1) Name	Kyoto University
(2) Location	Yoshida-honmachi, Sakyo-ku, Kyoto
(3) Representative	Nagahiro Minato, president
(4) Total number of students	22,486 (fiscal 2021)
(5) Capital	¥268,182 million (fully government-funded)
(6) Date of establishment	June 1897.

(7) Relationship with JCR	
Capital relationship	Not applicable
Personnel relationship	Not applicable
Transaction relationship	Not applicable
Relevant status towards related parties	Not applicable

This disposition of treasury stock is conducted as a donation to the Tasuku Honjo “Yuh- shi” Fund and the Cancer Immunotherapy Research Fund set up by Kyoto University, and the Company has designated to Kyoto University, the subscriber of this disposition, that this be incorporated as follows:

Tasuku Honjo “Yuh -shi” Fund	500,000 shares
Cancer Immunotherapy Research Fund	500,000 shares

The purposes of establishment, etc., of the two funds are as follows:

(1) Name	Kyoto University Tasuku Honjo “Yuh-shi” Fund
(2) Location	Yoshida-honmachi, Sakyo-ku, Kyoto
(3) Establisher	Norihiro Tokitoh, Executive Vice-President for Research, Kyoto University
(4) Objective of establishment	Support through salary and research funding over the long term for young researchers with high ideals and involved in life science or basic research

(1) Name	Kyoto University Cancer Immunotherapy Research Fund
(2) Location	Yoshida-honmachi, Sakyo-ku, Kyoto
(3) Establisher	Kazuhiro Iwai, Dean, Graduate School of Medicine, Kyoto University
(4) Objective of establishment	Strengthen the long-term financial base of the CCII, established as a comprehensive research institute for cancer immunotherapy research

For details regarding this matter, please refer to “Notice of Disposition of Treasury Stock through Third-Party Allotment for the Purpose of Making a Donation to Kyoto University” released on May 12, 2022.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 47-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-

Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

###